Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Genotropin Injector Pens in Healthy Adults
NCT07542886Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2026
- Primary completion
- Jun 2026
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of genotropin miniquick in growth hormone deficiency (GHD) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity at 24 hours and Maximum Observed Plasma Concentration at 24 hours. Started Apr 2026; status: completed.
02
Drugs
genotropin miniquick
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07542886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542886.